SEONGNAM, South Korea – PharmaResearch, a leading pharmaceutical/medical device research company, has announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, scheduled from April 5th to 10th in San Diego, California. The company will unveil research findings regarding its groundbreaking anticancer agent, PRD-101, through a poster session.
The presentations will cover diverse topics, including the efficacy demonstrated in various patient-derived xenograft (PDX) animal models and the results of in-depth characterization conducted by the National Cancer Institute’s Nanotechnology Characterization Laboratory (NCL).
Presentation Details
Poster Title: Efficient and safe delivery of doxorubicin by DNA fragments: A full preclinical study Date and Time: Tuesday April 9, 1:30 AM – 5:00 PM PT
Session Category: Chemistry
Session Title: Drug Delivery
Session Location: Section 20
Poster Board Number: 3
Abstract number: 5735
About PharmaResearch’s PRD-101
PRD-101 represents a significant advancement in cancer treatment, utilizing nucleotide fragments produced through PharmaResearch’s proprietary DNA optimization technology (DOTTM) in nano-particle anticancer formulations. Collaborative efforts between PharmaResearch and the University of California Irvine (UCI) researchers, along with support from organizations like the U.S. NCL, have propelled the development of PRD-101. PharmaResearch holds patents and exclusive license associated with PRD-101, marking a milestone in the company’s innovative endeavors.
Traditional anticancer drugs often face limitations due to high toxicity, which restricts patient eligibility and necessitates careful dosage management. PharmaResearch anticipates that PRD-101 will address these unmet medical needs in anticancer therapy. The company is committed to advancing quickly into clinical trials based on promising safety and efficacy results obtained from preclinical studies.
About PharmaResearch
PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life for humanity through regenerative medicine. With a diverse portfolio encompassing medicines, medical devices, cosmetics, and supplements, PharmaResearch focuses on leveraging its core ingredients, DOTTM PDRN and DOTTM PN. These active tissue regenerative substances are powered by DOTTM, an exclusive DNA fragments optimization technology safeguarded by a suite of patents. PharmaResearch is located in Seongnam, South Korea, and its US subsidiary, PharmaResarch USA is located in Costa Mesa, Califrornia, US.
PharmaResearch’s participation in the AACR Annual Meeting underscores its dedication to pioneering advancements in cancer research and treatment, ultimately aiming to improve patient outcomes and quality of life.
For more information about PharmaResearch and its innovative initiatives, visit http://pharmaresearch.co.kr/en
Media Contact
Company Name: PharmaResearch USA.
Contact Person: Sangjin Choi
Email: Send Email
Country: United States
Website: http://pharmaresearch.co.kr/en/